To cluster anal microbiota and define microbial patterns associated with biological, clinical, and behavioral correlates among Nigerian men who have sex with men (MSM) living with or at risk for HIV. In this cross-sectional pilot study, the 15 most abundant 16S taxa in the anal microbiota of 113 MSM underwent unsupervised K-means clustering and z-score comparisons to define similarities and dissimilarities among 4 microbiota taxonomic profiles. Distributions of oncogenic HPV (high-risk human papillomavirus [HR-HPV]), concurrent HIV, antiretroviral therapy (ART), and other clinical and behavioral data were evaluated using Fisher's exact and Kruskal–Wallis tests to determine biological signatures of cluster membership. Prevotella was consistently represented in each cluster, but the average composition ranged from 14% to 44%. Cluster 2 was enriched with a member of the Fusobacteria phylum, Sneathia (29%). More participants of cluster 2 were HIV infected and taking ART (83%, 5/6), were virally suppressed (80%, 4/5), had HPV-16 (66.7%, 4/6), and reported no vaginal sex partners (83%, 5/6). HPV-35, a highly prevalent oncogenic HPV in Nigeria, was observed in all clusters except cluster 2 (0%, 0/6). Other covariates were similar across clusters (all p > .05). K-means unsupervised clustering, a canonical pattern recognition method, generalized the microbial community composition and structure while accounting for among sample variability. Further studies are needed to evaluate whether an anal microbial community enriched with members of the Fusobacteria phylum is associated with HIV-infected MSM who are virally suppressed and have a concurrent HPV-16.
Get full access to this article
View all access options for this article.
References
1.
ShiZ, GewirtzAT: Together forever: Bacterial–viral interactions in infection and immunity. Viruses, 2018; 10:122.
2.
Noguera-JulianM, RocafortM, GuillénY, et al.: Gut microbiota linked to sexual preference and HIV infection. EBioMedicine, 2016; 5:135–146.
3.
YuG, FadroshD, MaB, RavelJ, GoedertJJ: Anal microbiota profiles in HIV-positive and HIV-negative MSM. AIDS, 2014; 28:753–760.
4.
NowakRG, BentzenSM, RavelJ, et al.: Rectal microbiota among HIV-uninfected, untreated HIV, and treated HIV-infected in Nigeria. AIDS, 2017; 31:857–862.
5.
ZevinAS, McKinnonL, BurgenerA, KlattNR: Microbial translocation and microbiome dysbiosis in HIV-associated immune activation. Curr Opin HIV AIDS, 2016; 11:182–190.
6.
MutluEA, KeshavarzianA, LosurdoJ, et al.: A compositional look at the human gastrointestinal microbiome and immune activation parameters in HIV infected subjects. PLoS Pathog, 2014; 10:e1003829.
7.
McHardyIH, LiX, TongM, et al.: HIV infection is associated with compositional and functional shifts in the rectal mucosal microbiota. Microbiome, 2013; 1:26.
8.
KelleyCF, KraftCS, de ManTJ, et al.: The rectal mucosa and condomless receptive anal intercourse in HIV-negative MSM: Implications for HIV transmission and prevention. Mucosal Immunol, 2017; 10:996–1007.
9.
PescatoreNA, PollakR, KraftCS, MulleJG, KelleyCF: Short communication: Anatomic site of sampling and the rectal mucosal microbiota in HIV negative men who have sex with men engaging in condomless receptive anal intercourse. AIDS Res Hum Retroviruses, 2018; 34:277–281.
10.
NowakP, TroseidM, AvershinaE, et al.: Gut microbiota diversity predicts immune status in HIV-1 infection. AIDS, 2015; 29:2409–2418.
11.
WuGD, BushmancFD, LewisJD: Diet, the human gut microbiota, and IBD. Anaerobe, 2013; 24:117–120.
12.
StanleyM: HPV—Immune response to infection and vaccination. Infect Agents Cancer, 2010; 5:19.
13.
GravittPE: The known unknowns of HPV natural history. J Clin Invest, 2011; 121:4593–4599.
14.
LinC, FranceschiS, CliffordGM: Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: A systematic review and meta-analysis. Infect Dis, 2018; 18:198–206.
15.
Serrano-VillarS, Vásquez-DomínguezE, Pérez-MolinaJA, et al.: HIV, HPV, and microbiota: Partners in crime?. AIDS, 2017; 31:591–594.
16.
LozuponeCA, RhodesME, NeffCP, FontenotAP, CampbellTB, PalmerBE: HIV-induced alteration in gut microbiota: Driving factors, consequences, and effects of antiretroviral therapy. Gut Microbes, 2014; 5:562–570.
17.
FaustK, SathirapongsasutiJF, IzardJ, et al.: Microbial co-occurrence relationships in the human microbiome. PLoS Comput Biol, 2012; 8:e1002606.
18.
LevyR, CarrR, KreimerA, FreilichS, BorensteinE: NetCooperate: A network-based tool for inferring host–microbe and microbe-microbe cooperation. BMC Bioinformatics, 2015; 16:164.
19.
MortonJT, SandersJ, QuinnRA, et al.: Balance trees reveal microbial niche differentiation. mSystems, 2017; 2:pii:e00162-16.
20.
RavelJ, GajerP, AbdoZ, et al.: Vaginal microbiome of reproductive-age women. Proc Natl Acad Sci U S A, 2011; 108(Suppl 1):4680–4687.
21.
GajerP, BrotmanRM, BaiG, et al.: Temporal dynamics of the human vaginal microbiota. Sci Transl Med, 2012; 4:132ra52.
22.
NowakRG, GravittPE, HeX, et al.: Prevalence of anal high-risk human papillomavirus infections among HIV-positive and HIV-negative men who have sex with men in Nigeria. Sex Transm Dis, 2016; 43:243–248.
23.
CharuratME, EmmanuelB, AkoloC, et al.: Uptake of treatment as prevention for HIV and continuum of care among HIV-positive men who have sex with men in Nigeria. J Acquir Immune Defic Syndr, 2015; 68(Suppl 2):S114–S123.
24.
BaralSD, KetendeS, SchwartzS, et al.: Evaluating respondent-driven sampling as an implementation tool for universal coverage of antiretroviral studies among men who have sex with men living with HIV. J Acquir Immune Defic Syndr, 2015; 68(Suppl 2):S107–S113.
25.
Federal Ministry of Health (FMOH): National Guidelines for HIV Prevention Treatment and Care. Federal ministry of Health Nigeria, 2016, pp. 19. Available at: http://apps.who.int/medicinedocs/documents/s23252en/s23252en.pdf
26.
EdgarRC: Search and clustering orders of magnitude faster than BLAST. Bioinformatics, 2010; 26:2460–2461.
27.
EdgarRC, HaasBJ, ClementeJC, QuinceC, KnightR: UCHIME improves sensitivity and speed of chimera detection. Bioinformatics, 2011; 27:2194–2200.
28.
WangQ, GarrityGM, TiedjeJM, ColeJR: Naive bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. Appl Environ Microbiol, 2007; 73:5261–5267.
29.
McDonaldD, PriceMN, GoodrichJ, et al.: An improved greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. ISME J, 2012; 6:610–618.
30.
HarwichMDJr., SerranoMG, FettweisJM, et al.: Genomic sequence analysis and characterization of Sneathia amnii sp. nov. BMC Genomics, 2012; 13(Suppl 8):S4.
31.
FredricksDN: Molecular methods to describe the spectrum and dynamics of the vaginal microbiota. Anaerobe, 2011; 17:191–195.
32.
LennardK, DabeeS, BarnabasSL, et al.: Microbial composition predicts genital tract inflammation and persistent bacterial vaginosis in South African adolescent females. Infect immun, 2017; 86:pii:e00410-17.
33.
ManhartLE, KhosropourCM, LiuC, et al.: Bacterial vaginosis-associated bacteria in men: Association of Leptotrichia/Sneathia spp with nongonococcal urethritis. Sex Transm Dis, 2013; 40:944–949.
34.
HanYW, ShenT, ChungP, BuhimschiIA, BuhimschiCS: Uncultivated bacteria as etiologic agents of intra-amniotic inflammation leading to preterm birth. J Clin Microbiol, 2009; 47:38–47.
35.
GosmannC, AnahtarMN, HandleySA, et al.: Lactobacillus-deficient cervicovaginal bacterial communities are associated with increased HIV acquisition in young south african women. Immunity, 2017; 46:29–37.
36.
NawrotR, KamieniarzK, MalinowskaM, et al.: The prevalence of Leptotrichia amnionii in cervical swabs of HPV positive and negative women. Eur J Gynaecol Oncol, 2010; 31:425–428.
37.
Audirac-ChalifourA, Torres-PovedaK, Bahena-RománM, et al.: Cervical microbiome and cytokine profile at various stages of cervical cancer: A pilot study. PloS One, 2016; 11:e0153274.
38.
Allen-VercoeE, JobinC: Fusobacterium and enterobacteriaceae: Important players for CRC?. Immunol Lett, 2014; 162:54–61.
39.
HanYW, ShiW, HuangGT, et al.: Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells. Infect Immun, 2000; 68:3140–3146.
40.
JewettA, HumeWR, LeH, et al.: Induction of apoptotic cell death in peripheral blood mononuclear and polymorphonuclear cells by an oral bacterium, Fusobacterium nucleatum. Infect Immun, 2000; 68:1893–1898.
41.
LeeJE, LeeS, LeeH, et al.: Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PloS One, 2013; 8:e63514.
42.
BrotmanRM, ShardellMD, GajerP, et al.: Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J Infect Dis, 2014; 210:1723–1733.
43.
MitraA, MacIntyreDA, LeeYS, et al.: Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci Rep, 2015; 5:16865.
44.
TaylorS, BungeE, BakkerM, CastellsaguéX: The incidence, clearance and persistence of non-cervical human papillomavirus infections: A systematic review of the literature. BMC Infect Dis, 2016; 16:293.
45.
BurkRD, HarariA, ChenZ: Human papillomavirus genome variants. Virology, 2013; 445:232–243.
46.
GoedertJJ: The microbiota and HIV: Shedding light on dark matters. AIDS, 2017; 31:863–865.
47.
JacksonMA, GoodrichJK, MaxanME, et al.: Proton pump inhibitors alter the composition of the gut microbiota. Gut, 2016; 65:749–756.
48.
KlaseZ, OrtizA, DeleageC, et al.: Dysbiotic bacteria translocate in progressive SIV infection. Mucosal Immunol, 2015; 8:1009–1020.
49.
Vujkovic-CvijinI, DunhamRM, IwaiS, et al.: Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med, 2013; 5:193ra91.
50.
Doléans-JordheimA, BergeronE, BereyziatF, et al.: Zidovudine (AZT) has a bactericidal effect on enterobacteria and induces genetic modifications in resistant strains. Eur J Clin Microbiol Infect Dis, 2011; 30:1249–1256.
51.
McgowanI, CranstonRD, DuffillK, et al.: A phase 1 randomized, open label, rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of three formulations of tenofovir 1% gel (the CHARM-01 study). PloS One, 2015; 10:e0125363.
52.
KlattNR, CheuR, BirseK, et al.: Vaginal bacteria modify HIV tenofovir microbicide efficacy in African women. Science, 2017; 356:938–945.
53.
HeffronR, McClellandRS, BalkusJE, et al.: Efficacy of oral pre-exposure prophylaxis (PrEP) for HIV among women with abnormal vaginal microbiota: A post-hoc analysis of the randomised, placebo-controlled partners PrEP study. Lancet, 2017; 4:e449–e456.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
